Drugs / VX-864
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05643495 | Feb 2023 → Aug 2024 | alpha 1-antitrypsin deficiency | Vertex Pharmaceuticals Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT04474197 | Jul 2020 → May 2021 | alpha 1-antitrypsin deficiency | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-10 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency vrtx.com ↗
Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-10 | Vertex Pharmaceuticals Incorporated | Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-864 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04474197 ↗ |
| Route | Oral | “Tablets for oral administration.” NCT04474197 ↗ |